Sahin Ozlem G
Department of Ophthalmology, Middle East Technical University Health Center, Ankara, Turkey.
Case Rep Ophthalmol. 2011 Sep;2(3):367-75. doi: 10.1159/000335175. Epub 2011 Dec 13.
To report a case of Behcet's panuveitis and unilateral inflammatory maculopathy which was refractory to conventional immunosuppressive therapy but responded well to long-term treatment with the tumor necrosis factor-alpha inhibitor infliximab.
Reporting the effect of intravenous infliximab infusion therapy for 54 weeks in a case of Behcet's panuveitis and unilateral inflammatory maculopathy. The patient's best corrected visual acuity was monitored, and biomicroscopic and fundus examinations as well as macular thickness map analysis by stratus optical coherence tomography were performed.
The best corrected visual acuity in his right eye improved after the resolution of inflammatory signs on biomicroscopic and fundus examinations as well as on stratus optical coherence tomography macular thickness analysis reports. No significant systemic side effects were noted.
Long-term therapy with infliximab is effective and safe for refractory inflammatory maculopathy in Behcet's disease. We report this case to contribute to the few previously reported cases showing the beneficial effect of long-term infliximab therapy for Behcet's panuveitis. In conclusion, early initiation of infliximab therapy for inflammatory maculopathy in Behcet's disease preserves and improves visual acuity.
报告一例白塞氏全葡萄膜炎和单侧炎性黄斑病变患者，该患者对传统免疫抑制治疗无效，但长期使用肿瘤坏死因子-α抑制剂英夫利昔单抗治疗效果良好。
报告静脉输注英夫利昔单抗54周对一例白塞氏全葡萄膜炎和单侧炎性黄斑病变患者的疗效。监测患者的最佳矫正视力，并进行生物显微镜检查、眼底检查以及通过Stratus光学相干断层扫描进行黄斑厚度图分析。
在生物显微镜检查、眼底检查以及Stratus光学相干断层扫描黄斑厚度分析报告显示炎症体征消退后，其右眼的最佳矫正视力有所提高。未观察到明显的全身副作用。
英夫利昔单抗长期治疗对白塞氏病难治性炎性黄斑病变有效且安全。我们报告此病例以补充之前少数关于英夫利昔单抗长期治疗对白塞氏全葡萄膜炎有益效果的报道病例。总之，对白塞氏病炎性黄斑病变早期启动英夫利昔单抗治疗可保留并提高视力。
